Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML

Veit Bücklein, MD, Thomas Köhnke, MD, Frauke Schnorfeil, PhD, Klaus H. Metzeler, MD, Nikola P Konstandin, PhD, Annika Maria Dufour, PhD, Cristina Sauerland, Wolfgang Hiddemann, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2018) 132 (Supplement 1): 2753.

https://doi.org/10.1182/blood-2018-99-119065

Published: 2018

Journal Articles

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Christina Krupka, Bettina Lindl, Thomas Köhnke, MD, Julia Platzer, Lavinia Pachzelt, Felix S Lichtenegger, MD, Torben Altmann, Peter Kufer, MD, Roman Kischel, MD, Wolfgang Hiddemann, MD, PhD, Marion Subklewe, MD

Blood (2016) 128 (22): 3940.

https://doi.org/10.1182/blood.V128.22.3940.3940

Published: 2016

Journal Articles

Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome

Blood (2016) 128 (22): 2224.

https://doi.org/10.1182/blood.V128.22.2224.2224

Published: 2016

Journal Articles

Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade

Felix S. Lichtenegger, MD, Katrin Deiser, PhD, Maurine Rothe, Frauke M. Schnorfeil, PhD, Christina Krupka, PhD, Christian Augsberger, Thomas Köhnke, MD, Veit L. Bücklein, MD, Torben Altmann, MD, Andreas Moosmann, Monika Brüggemann, MD PhD, Mirjam H.M. Heemskerk, PhD, Georg Wittmann, MD, Beate Wagner, MD, Wolfgang Hiddemann, MD, Iris Bigalke, PhD, Gunnar Kvalheim, MD PhD, Marion Subklewe, MD

Blood (2016) 128 (22): 764.

https://doi.org/10.1182/blood.V128.22.764.764

Published: 2016

Journal Articles

Improved Detection of Minimal Residual Disease By Flow Cytometry in AML By Combining Manual Gating and Visne Clustering

Thomas Köhnke, MD, Sandra Rechkemmer, Veit Leonhard Bücklein, MD, Kristina Pfannes, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Marion Subklewe, MD

Blood (2015) 126 (23): 2593.

https://doi.org/10.1182/blood.V126.23.2593.2593

Published: 2015

Journal Articles

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Christina Krupka, Thomas Köhnke, MD, Peter Kufer, Roman Kischel, Felix S. Lichtenegger, Franziska Brauneck, Stefan Rohling, Torben Altmann, Wolfgang Hiddemann, MD PhD, Marion S. Subklewe, MD

Blood (2015) 126 (23): 3677.

https://doi.org/10.1182/blood.V126.23.3677.3677

Published: 2015

Journal Articles

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Dusan Prevalsek, MD, Susanne Fritsch, MD, Max Hubmann, MD, Nicole Engel, MD, Anna-Katharina Zoellner, MD, Thomas Köhnke, MD, Veit Leonhard Bücklein, MD, Christoph Schulz, MD, Friederike Mumm, MD, Christina Theresa Rieger, MD, Georg Ledderose, MD, Hans-Joachim Stemmler, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Andreas Hausmann, MD, Johanna Tischer, MD

Blood (2015) 126 (23): 4318.

https://doi.org/10.1182/blood.V126.23.4318.4318

Published: 2015

Journal Articles

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Christina Krupka, Franziska Brauneck, Felix S Lichtenegger, MD, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 986.

https://doi.org/10.1182/blood.V124.21.986.986

Published: 2014

Journal Articles

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

Christina Krupka, Anna Jansen, Irène Lassmann, Jon Terrett, PhD, Dee Aud, Rachel Dusek, PhD, Arnima Bisht, PhD, Esteban Pombo-Villar, PhD, Christian Rohlff, PhD, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Torben Altmann, MD, Klaus H Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Wolfgang Hiddemann, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 987.

https://doi.org/10.1182/blood.V124.21.987.987

Published: 2014

Journal Articles

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Frauke M Schnorfeil, PhD, Torben Altmann, MD, Stephanie Schneider, PhD, Michael Fiegl, MD, Karsten Spiekermann, MD, Angus M Sinclair, PhD, Kathryn J Newhall, PhD, Stanley R Frankel, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, MD, Marion Subklewe, MD

Blood (2014) 124 (21): 3738.

https://doi.org/10.1182/blood.V124.21.3738.3738

Published: 2014

Journal Articles

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Christina Krupka, Peter Kufer, Roman Kischel, Gerhard Zugmaier, Jan Bögeholz, Thomas Köhnke, Felix S. Lichtenegger, Stephanie Schneider, Klaus H. Metzeler, Michael Fiegl, Karsten Spiekermann, Patrick A. Baeuerle, Wolfgang Hiddemann, Gert Riethmüller, Marion Subklewe

Blood (2014) 123 (3): 356–365.

https://doi.org/10.1182/blood-2013-08-523548

Published: 2014

Includes: Supplemental data

Journal Articles

Proposal For a Novel Scoring System For The Diagnosis Of CLL

Thomas Köhnke, MD, Veronika K Wittmann, Daniela Sauter, MD, Veit Bücklein, MD, Zlatana Pasalic, Wolfgang Hiddemann, MD, Karsten Spiekermann, MD, Marion Subklewe, MD

Blood (2013) 122 (21): 4150.

https://doi.org/10.1182/blood.V122.21.4150.4150

Published: 2013

Journal Articles

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Christina Krupka, Peter Kufer, MD, Roman Kischel, MD, Gerhard Zugmaier, Jan Boegeholz, Thomas Köhnke, MD, Felix S Lichtenegger, MD, Stephanie Schneider, PhD, Klaus H. Metzeler, MD, Michael Fiegl, MD, Karsten Spiekermann, MD, Patrick Baeuerle, PhD, Wolfgang Hiddemann, MD, Gert Riethmüller, Marion Subklewe, MD

Blood (2013) 122 (21): 239.

https://doi.org/10.1182/blood.V122.21.239.239

Published: 2013

NARROW

Minimal Residual Disease (MRD) Detection By Flow Cytometry Complements Molecular MRD Assessment in AML

Steroids Abrogate BiTE ® Antibody Construct-Mediated Cytotoxicity in Primary AML Cells

Alternative Donor Transplantation Using Intensified Conditioning, T-Cell-Replete HLA-Haploidentical Grafts and Post-Transplantation Cyclophosphamide in the Treatment of High-Risk and Advanced ALL: Feasibility and Outcome

Induction of Antigen-Specific T-Cell Responses through Dendritic Cell Vaccination in AML: Results of a Phase I/II Trial and Ex Vivo Enhancement By Checkpoint Blockade

Improved Detection of Minimal Residual Disease By Flow Cytometry in AML By Combining Manual Gating and Visne Clustering

Identifying Immune Resistance Mechanisms to CD33/CD3 BiTE® Antibody Construct (AMG 330) Mediated Cytotoxicity

Feasibility and Outcome of Sequential Therapy in the Setting of HLA-Haploidentical Transplantation Utilizing Reduced-Intensity Conditioning, T-Cell-Replete Grafts and Post-Transplantation High-Dose Cyclophosphamide in the Treatment of High-Risk AML and MDS

Hydroxyurea Is Most Suitable for Cytoreduction of AML Prior to CD33/CD3 Bispecific BiTE® Antibody (AMG 330) Therapy: Uncompromised T-Cell Proliferation Ex-Vivo and CD33 Upregulation on AML Cells

Targeting AML Using an Fc-Engineered BST1/CD157 Monoclonal Antibody

PD-1/PD-L1 Blocking Enhances CD33/CD3-Bispecific BiTE® Antibody (AMG 330) Mediated Lysis of Primary AML Cells

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Proposal For a Novel Scoring System For The Diagnosis Of CLL

Evaluation Of CD33 Expression and Functional Analysis Of The CD33/CD3 Bispecific BiTE® Antibody AMG 330 In Primary AML Samples

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only